Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, LTD. (KAPA) on July 15, 2026. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Los Angeles, CA. The report addresses Item 8.01 (Other Events) regarding clinical trial updates.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial update and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is the issuance of a press release on July 15, 2026, detailing interim safety data from an ongoing Phase 1 clinical trial. The trial evaluates the Company's investigational drug ENV-105 (Carotuximab) in combination with osimertinib for patients with advanced EGFR-mutated non-small cell lung cancer.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary beyond the announcement of the safety data release. The report includes a standard disclaimer stating that the information furnished, including the press release (Exhibit 99.1), is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific details on the interim safety data.
- Verify the current status and enrollment numbers of the Phase 1 trial for ENV-105.
- Confirm the Company's cash runway and funding status, as this filing does not disclose liquidity metrics.
- Monitor future filings for any changes in the trial design or additional safety signals.